Traditional vaccines, involving inactivated or attenuated viral particles, have decades of research supporting their safety and effectiveness, i.e., their ability to stop transmission in the real world and not only in randomized controlled trials, with no major adverse effects. Still, vaccination is not mandatory in Canada17, so mandating COVID products in schools - as they currently are in post-secondary educational establishments - would be unprecedented in Canadian history. Such mandates are also a major violation of the right to informed consent, which by definition must be free from coercion.18 In the case of the very young, it is also a major violation of the right of parents to decide on the medical procedures performed on their children.
5) COVID-19 vaccine products are not safe - for adults or children
Several countries have stopped using COVID products in the young. Finland, Sweden and Denmark no longer use them in the population under 30 years of age due to concerns about myocarditis.19 A retrospective assessment of reports filed to the US Vaccine Adverse Event Reporting System (VAERS) between January 1, 2021, and June 18, 2021, among healthy adolescents ages 12-17 who received COVID products, identified that this age group was up to six times more likely to be diagnosed with myocarditis than to be hospitalized for COVID-19.20
In Canada, a recent SickKids report notes that heart disease among the young - myocarditis and pericarditis - have risen since the launch of the vaccination campaign, and instructs clinicians on treatment of adverse events post injection - abdominal pain, vomiting, encephalopathy, and in some severe cases, hypertension and shock among others.21 Considering that only 16 of 1,129 participants in the control group of the Pfizer trial tested positive for COVID-1922 - of note, a positive test is not necessarily illness - whereas in the treatment group 3 in 4 participants experienced fatigue and headaches, around half muscle pain, and 1 in 4 joint pain, the relative benefits of the COVID-19 products remain at best dubious.4
Additionally, phase
III trials are the highest level of evidence and our best tool for ascertaining
the risks and benefits of a treatment. Results from the phase III trial of the Pfizer/BioNTech
BNT162b2 mRNA product through 6 months were recently reported by Thomas et al. in the New England Journal of Medicine.23 The study, which compared the
mRNA COVID-19 vaccine to placebo in healthy adults, showed an absolute risk
reduction (ARR) in symptomatic and PCR-confirmed COVID-19 cases among fully
vaccinated individuals of 3.7%, but an absolute risk increase (ARI) of 17.9% in treatment-related adverse effects in that same group. As well, the
study reported an ARR in severe COVID-19 cases of 0.1% among the fully
vaccinated, but also an ARI in serious adverse events among vaccine
recipients of 0.5%. While deaths were relatively comparable across arms
initially (15 vs 14 deaths, vaccine vs placebo, respectively), 5 additional
deaths were reported in vaccine recipients after cross over, bringing the total
death count after vaccination to 20. (Table 1). Of note, there were nearly
twice as many deaths due to cardiac events in the vaccine arm compared to the
placebo arm (7 vs 4 deaths). Results of the BNT162b2 mRNA COVID-19 phase
III clinical trial clearly demonstrate at the highest level of evidence that
the risks associated with the BNT162b2 mRNA COVID-19 vaccine outweigh the risks
of COVID-19 in healthy adults, and do not support claims about the safety of
these products, in this or any other population, and regardless of antibody
levels.
Finally, vaccine safety-reporting systems are revealing a record number of injuries. As of October 15, 2021, reported adverse events worldwide had surpassed 2,344,240 in the WHO reporting system Vigiaccess.24 VAERS recorded 122,833 serious adverse events, 17,128 of which ended in death, post administration of COVID products. For context, the combined serious adverse events, including deaths, upon administering all (around 70) vaccines, except for COVID products, that have been reported to VAERS since 1990 when the system was established, was 103,767 and 9,054, respectively.25 Put another way, about 50% of serious adverse events ever recorded in the over 30 years of the existence of VAERS were associated with three COVID products (AstraZeneca's product was not approved in the USA) within less than one year. Even these staggering numbers underreport the true adverse events post COVID products by a factor of at least 1026 and likely as high as 41.27
VAERS data from October 22, 2021, for 12- to 17-year-olds specifically revealed:
 · 22,212 total adverse events, [1] including 1,348 rated as serious [2] and 25 reported deaths (2 were suicides).
 · 58 reports of anaphylaxis among 12- to 17-year-olds where the reaction was life-threatening, required treatment, or resulted in death. [3]
 · 539 reports of myocarditis and pericarditis
(heart inflammation). [4]
 · 125 reports of blood clotting disorders. [5]
A recent death involved a 12-year-old girl (VAERS I.D. 1784945) who died from a respiratory tract hemorrhage 22 days after receiving her first Pfizer product dose. Another recent death is the case of a 16-year-old girl (VAERS I.D. 1694568) who died of pulmonary embolism 9 days after a Pfizer product dose (whether it was the first or second is unknown). Yet another recent death was that of a 15-year-old boy who died six days after receiving his first dose of Pfizer product. The VAERS report (I.D. 1764974) states that the previously healthy teen 'was in his usual state of good health. Five days after the vaccine, he complained of shoulder pain. He was playing with 2 friends at a community pond, swinging from a rope swing, flipping in the air, and landing in the water feet first. He surfaced, laughed, told his friends "Wow, that hurt!", then swam toward shore, underwater as was his usual routine. The friends became worried when he did not re-emerge. His body was retrieved by local authorities more than an hour later.' The autopsy revealed 'small foci of myocardial inflammation', an adverse effect of these COVID products commonly found among children and youth, particularly young men.
Of note, none of these reports include long-term adverse events, critical to assessing the safety of any medical product. If the history of drug development - such as that of thalidomide, dengue vaccine, and swine flu vaccine - teaches us anything, it is that the harm caused by implementing "remedies" that have not been properly tested can be much greater than the harm caused by the "disease" that these remedies are designed to treat. 28-30
In concluding, we thank you for taking the time to read our analysis, expect it will contribute to your efforts to keep young Ontarians safe, and would appreciate the opportunity to engage and collaborate with you and members of your team towards that goal.
Respectfully,
Next Page 1 | 2 | 3 | 4 | 5 | 6 | 7 | 8 | 9 | 10
(Note: You can view every article as one long page if you sign up as an Advocate Member, or higher).
1
1
1
